Suncoast Equity Management Increases Position in Zoetis Inc. $ZTS

Suncoast Equity Management boosted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 4.0% in the 2nd quarter, Holdings Channel reports. The fund owned 12,256 shares of the company’s stock after acquiring an additional 467 shares during the quarter. Suncoast Equity Management’s holdings in Zoetis were worth $1,911,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Waverton Investment Management Ltd grew its stake in Zoetis by 1.1% during the 2nd quarter. Waverton Investment Management Ltd now owns 339,946 shares of the company’s stock valued at $52,989,000 after acquiring an additional 3,585 shares in the last quarter. Resona Asset Management Co. Ltd. grew its stake in Zoetis by 10.3% during the 2nd quarter. Resona Asset Management Co. Ltd. now owns 402,029 shares of the company’s stock valued at $62,707,000 after acquiring an additional 37,618 shares in the last quarter. Atlantic Union Bankshares Corp grew its stake in Zoetis by 872.3% during the 2nd quarter. Atlantic Union Bankshares Corp now owns 61,227 shares of the company’s stock valued at $9,548,000 after acquiring an additional 54,930 shares in the last quarter. GPS Wealth Strategies Group LLC grew its stake in Zoetis by 20.2% during the 2nd quarter. GPS Wealth Strategies Group LLC now owns 465 shares of the company’s stock valued at $72,000 after acquiring an additional 78 shares in the last quarter. Finally, NewSquare Capital LLC grew its stake in Zoetis by 69.1% during the 2nd quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after acquiring an additional 85 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of ZTS stock opened at $120.47 on Thursday. The firm’s 50 day moving average price is $145.63 and its 200-day moving average price is $153.01. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. Zoetis Inc. has a one year low of $119.07 and a one year high of $181.85. The firm has a market cap of $53.39 billion, a P/E ratio of 20.73, a P/E/G ratio of 2.31 and a beta of 0.90.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.62 by $0.08. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.42 billion. During the same period in the prior year, the business posted $1.58 EPS. The business’s revenue for the quarter was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities research analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 1.7%. The ex-dividend date is Friday, October 31st. Zoetis’s dividend payout ratio is currently 34.42%.

Analyst Ratings Changes

Several analysts recently issued reports on ZTS shares. Leerink Partners cut shares of Zoetis from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Stifel Nicolaus set a $140.00 target price on shares of Zoetis in a report on Tuesday. Argus reiterated a “buy” rating and issued a $190.00 target price on shares of Zoetis in a report on Tuesday, September 9th. Leerink Partnrs lowered shares of Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Finally, Piper Sandler boosted their target price on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Five research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $191.00.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.